The High Court in Pretoria has declared the main contracts in the Health Department’s R15.5 billion ARV tender unconstitutional and invalid. The court set aside two contracts for monthly and three-monthly packs of tenofovir, lamivudine and dolutegravir (TLD), worth a combined R12.63 billion. TLD is the triple combination pill taken by most of South Africa’s HIV-positive patients. According to Treasury,…
Tag: Cipla
-
Pharma Giants Sidelined in R15.5bn HIV Drug Tender
The National Department of Health has awarded its latest three-year antiretroviral (ARV) tender, valued at R15.5 billion. This decision leaves several of South Africa’s largest domestic pharmaceutical manufacturers without a contract. The government’s procurement strategy sidelines pharma giants and sparks a fresh debate. This debate pits aggressive cost-saving measures against its stated goal of bolstering local industrial capacity. The tender…
-
Cipla Medpro faces claims over side effects of antibiotic
Cipla Medpro faces claims that it failed to adequately warn patients about the potentially severe side effects of a common antibiotic. These claims arose after a Johannesburg man suffered four life-altering tendon ruptures. A man in his 40s is now considering legal action against the company. He was prescribed Tavaloxx, a fluoroquinolone antibiotic, and alleges the warnings provided inside the…
-
Adcock Ingram’s Urizone Wins Trademark Battle
A South African court has ruled in favour of Adcock Ingram and Zambon SPA. It ordered Cipla Medpro to stop using the trademark Furizome for its urinary tract infection (UTI) medication. The court found Furizome to be confusingly similar to the established Urizone trademark, central to Adcock Ingram’s branding strategy. This led to a ruling based on trademark infringement and…